KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Adaptive Biotechnologies (ADPT) Net Margin (2018 - 2025)

Adaptive Biotechnologies (ADPT) has disclosed Net Margin for 8 consecutive years, with 18.94% as the latest value for Q4 2025.

  • Quarterly Net Margin rose 5210.0% to 18.94% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 21.47% through Dec 2025, up 6771.0% year-over-year, with the annual reading at 21.47% for FY2025, 6771.0% up from the prior year.
  • Net Margin hit 18.94% in Q4 2025 for Adaptive Biotechnologies, down from 10.16% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 10.16% in Q3 2025 to a low of 620.92% in Q2 2023.
  • Historically, Net Margin has averaged 125.77% across 5 years, with a median of 110.3% in 2024.
  • Biggest five-year swings in Net Margin: crashed -50163bps in 2023 and later surged 51384bps in 2024.
  • Year by year, Net Margin stood at 161.76% in 2021, then soared by 55bps to 72.77% in 2022, then plummeted by -108bps to 151.73% in 2023, then surged by 53bps to 71.04% in 2024, then soared by 73bps to 18.94% in 2025.
  • Business Quant data shows Net Margin for ADPT at 18.94% in Q4 2025, 10.16% in Q3 2025, and 43.47% in Q2 2025.